← SynDRA
TAK-715
SynDRA canonical compound SYN0005987 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAPK14 |
|---|
| Mechanism of action | P38 MAPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
- MAPK11 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- PLK3
- MKNK2
- NEK2
- NEK4
- NTRK1
- NTRK2
- NTRK3
- PAK1
- PAK4
- PBK
- PDPK1
- PHKG2
- PIM1
- PIM2
- PIM3
- PKN2
- MINK1
- MET
- MELK
- MAPK3
- MAP4K2
- MAP4K4
- MAP4K5
- MAPK1
- MAPK12
- MAPK13
- MAPK8
- MATK
- MAPK9
- MAPKAPK2
- MAPKAPK3
- MAPKAPK5
- MARK2
- MARK3
- PLK1
- PLK4
- MAP3K20
- PRKAA1
- RPS6KA5
Cross-references
Synonyms
- TAK 715
- P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda
- WE92U03C5Z
- RefChem:187198
- DTXCID30106903
- N-(4-(2-ethyl-4-(m-tolyl)thiazol-5-yl)pyridin-2-yl)benzamide
- TAK715
- MFCD17012805
- N-[4-[2-ethyl-4-(m-tolyl)thiazol-5-yl]-2-pyridyl]benzamide
- UNII-WE92U03C5Z
- C24H21N3OS
- T75
- Kinome_2655
- MLS006011241
- SCHEMBL297487
- GTPL9328
- orb1301032
- SCHEMBL29350215
- SCHEMBL29435089
- CHEBI:91360
- TAK0715
- HMS3244J06
- HMS3244J10
- HMS3244J14
- HMS3265K09
- HMS3265K10
- HMS3265L09
- HMS3265L10
- HMS3651N12
- EX-A2443
- BDBM50173609
- HB0599
- NSC785339
- s2928
- AKOS015904193
- CCG-268646
- CS-0073
- NSC-785339
Look up TAK-715 in the interactive SynDRA portal →